| 前收盘价格 | 1.01 |
| 收盘价格 | 1.04 |
| 成交量 | 69,810 |
| 平均成交量 (3个月) | 20,439 |
| 市值 | 12,485,222 |
| 价格/销量 (P/S) | 10.65 |
| 52周波幅 | |
| 利润日期 | 16 Sep 2025 - 22 Sep 2025 |
| 营业利益率 (TTM) | -1,264.64% |
| 稀释每股收益 (EPS TTM) | -3.63 |
| 季度收入增长率 (YOY) | 501.40% |
| 总债务/股东权益 (D/E MRQ) | 6,456.94% |
| 流动比率 (MRQ) | 4.81 |
| 营业现金流 (OCF TTM) | -17.31 M |
| 杠杆自由现金流 (LFCF TTM) | -11.34 M |
| 资产报酬率 (ROA TTM) | -36.57% |
| 股东权益报酬率 (ROE TTM) | -1,833.59% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Pluri Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | 0.00 |
|
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 43.87% |
| 机构持股比例 | 19.40% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Winch Advisory Services, Llc | 30 Jun 2026 | 26 |
| Tfc Financial Management, Inc. | 30 Jun 2026 | 19 |
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合